Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.

Hepatol Commun · 2020 · PMC7327222 · PMID 32626838

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendP = 0.075so close (0.05 < p ≤ 0.1)

( 24 ) In CheckMate‐459 , nivolumab treatment showed a trend toward improvement in OS (HR, 0.85; 95% CI, 0.71‐1.02; P = 0.075).

also in 53,322 other papers

a clear trendno p-value reported

However, the results of both trials showed a clear trend toward improvement in oncological outcomes.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.